File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines

TitleRecombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines
Authors
KeywordsAdeno-associated virus
Neutralizing antibodies
Receptor-binding domain
SARS-CoV
Spike protein
Vaccines
Issue Date2006
PublisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/yviro
Citation
Virology, 2006, v. 353 n. 1, p. 6-16 How to Cite?
AbstractDevelopment of an effective vaccine for severe acute respiratory syndrome (SARS) remains to be a priority to prevent possible re-emergence of SARS coronavirus (SARS-CoV). We previously demonstrated that the receptor-binding domain (RBD) of SARS-CoV S protein is a major target of neutralizing antibodies. This suggests that the RBD may serve as an ideal vaccine candidate. Recombinant adeno-associated virus (rAAV) has been proven to be an effective system for gene delivery and vaccine development. In this study, a novel vaccine against SARS-CoV was developed based on the rAAV delivery system. The gene encoding RBD was cloned into a pAAV-IRES-hrGFP plasmid. The immunogenicity induced by the resulting recombinant RBD-rAAV was evaluated in BALB/c mice. The results demonstrated that (1) a single dose of RBD-rAAV vaccination could induce sufficient neutralizing antibody against SARS-CoV infection; (2) two more repeated doses of the vaccination boosted the neutralizing antibody to about 5 times of the level achieved by a single dose of the immunization and (3) the level of the antibody continued to increase for the entire duration of the experiment of 5.5 months. These results suggested that RBD-rAAV is a promising SARS candidate vaccine. © 2006 Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/147544
ISSN
2015 Impact Factor: 3.2
2015 SCImago Journal Rankings: 1.805
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorDu, Len_HK
dc.contributor.authorHe, Yen_HK
dc.contributor.authorWang, Yen_HK
dc.contributor.authorZhang, Hen_HK
dc.contributor.authorMa, Sen_HK
dc.contributor.authorWong, CKLen_HK
dc.contributor.authorWu, SHWen_HK
dc.contributor.authorNg, Fen_HK
dc.contributor.authorHuang, JDen_HK
dc.contributor.authorYuen, KYen_HK
dc.contributor.authorJiang, Sen_HK
dc.contributor.authorZhou, Yen_HK
dc.contributor.authorZheng, BJen_HK
dc.date.accessioned2012-05-29T06:04:29Z-
dc.date.available2012-05-29T06:04:29Z-
dc.date.issued2006en_HK
dc.identifier.citationVirology, 2006, v. 353 n. 1, p. 6-16en_HK
dc.identifier.issn0042-6822en_HK
dc.identifier.urihttp://hdl.handle.net/10722/147544-
dc.description.abstractDevelopment of an effective vaccine for severe acute respiratory syndrome (SARS) remains to be a priority to prevent possible re-emergence of SARS coronavirus (SARS-CoV). We previously demonstrated that the receptor-binding domain (RBD) of SARS-CoV S protein is a major target of neutralizing antibodies. This suggests that the RBD may serve as an ideal vaccine candidate. Recombinant adeno-associated virus (rAAV) has been proven to be an effective system for gene delivery and vaccine development. In this study, a novel vaccine against SARS-CoV was developed based on the rAAV delivery system. The gene encoding RBD was cloned into a pAAV-IRES-hrGFP plasmid. The immunogenicity induced by the resulting recombinant RBD-rAAV was evaluated in BALB/c mice. The results demonstrated that (1) a single dose of RBD-rAAV vaccination could induce sufficient neutralizing antibody against SARS-CoV infection; (2) two more repeated doses of the vaccination boosted the neutralizing antibody to about 5 times of the level achieved by a single dose of the immunization and (3) the level of the antibody continued to increase for the entire duration of the experiment of 5.5 months. These results suggested that RBD-rAAV is a promising SARS candidate vaccine. © 2006 Elsevier Inc. All rights reserved.en_HK
dc.languageengen_US
dc.publisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/yviroen_HK
dc.relation.ispartofVirologyen_HK
dc.subjectAdeno-associated virusen_HK
dc.subjectNeutralizing antibodiesen_HK
dc.subjectReceptor-binding domainen_HK
dc.subjectSARS-CoVen_HK
dc.subjectSpike proteinen_HK
dc.subjectVaccinesen_HK
dc.subject.meshAnimalsen_US
dc.subject.meshAntibodies, Viral - Biosynthesisen_US
dc.subject.meshCell Lineen_US
dc.subject.meshDependovirus - Genetics - Metabolismen_US
dc.subject.meshFemaleen_US
dc.subject.meshGenetic Vectorsen_US
dc.subject.meshHela Cellsen_US
dc.subject.meshHumansen_US
dc.subject.meshMiceen_US
dc.subject.meshMice, Inbred Balb Cen_US
dc.subject.meshNeutralization Testsen_US
dc.subject.meshProtein Structure, Tertiaryen_US
dc.subject.meshReceptors, Virus - Metabolismen_US
dc.subject.meshRecombinant Proteins - Metabolismen_US
dc.subject.meshSars Virus - Immunologyen_US
dc.subject.meshViral Vaccines - Immunologyen_US
dc.titleRecombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccinesen_HK
dc.typeArticleen_HK
dc.identifier.emailHuang, JD:jdhuang@hkucc.hku.hken_HK
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_HK
dc.identifier.emailZheng, BJ:bzheng@hkucc.hku.hken_HK
dc.identifier.authorityHuang, JD=rp00451en_HK
dc.identifier.authorityYuen, KY=rp00366en_HK
dc.identifier.authorityZheng, BJ=rp00353en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.virol.2006.03.049en_HK
dc.identifier.pmid16793110-
dc.identifier.scopuseid_2-s2.0-33748142971en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33748142971&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume353en_HK
dc.identifier.issue1en_HK
dc.identifier.spage6en_HK
dc.identifier.epage16en_HK
dc.identifier.isiWOS:000240512100002-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridDu, L=8686996200en_HK
dc.identifier.scopusauthoridHe, Y=8742157400en_HK
dc.identifier.scopusauthoridWang, Y=14326142100en_HK
dc.identifier.scopusauthoridZhang, H=14326512500en_HK
dc.identifier.scopusauthoridMa, S=26028397100en_HK
dc.identifier.scopusauthoridWong, CKL=36862848200en_HK
dc.identifier.scopusauthoridWu, SHW=14326090600en_HK
dc.identifier.scopusauthoridNg, F=7103125273en_HK
dc.identifier.scopusauthoridHuang, JD=8108660600en_HK
dc.identifier.scopusauthoridYuen, KY=36078079100en_HK
dc.identifier.scopusauthoridJiang, S=7404453146en_HK
dc.identifier.scopusauthoridZhou, Y=8791655300en_HK
dc.identifier.scopusauthoridZheng, BJ=7201780588en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats